MarketCap
Facebook
X
TelegramAnnual report 2022
added 02-27-2023
Signify Health EBITDA 2011-2026 | SGFY
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Signify Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.3 M | 64 M | 28.3 M | 57.2 M | 35.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64 M | 28.3 M | 49.7 M |
Quarterly EBITDA Signify Health
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -71.7 M | - | 28.5 M | 3.7 M | 30.1 M | 42.8 M | 18.6 M | 9.2 M | 14.1 M | 29.4 M | 10.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 42.8 M | -71.7 M | 11.6 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Health information services industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
-38.6 M | - | 0.29 % | $ 206 M |  USA |
 |
Cerner Corporation
CERN
|
1.43 B | - | - | $ 27.9 B | USA |
 |
Computer Programs and Systems
CPSI
|
-40.7 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
148 M | - | - | $ 2.94 B | USA |
 |
Change Healthcare
CHNG
|
691 M | - | - | $ 9.03 B | USA |
 |
Castlight Health, Inc.
CSLT
|
-5.95 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
140 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
187 M | - | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
-6.03 M | - | - | $ 102 M | USA |
 |
Evolent Health
EVH
|
70.8 M | $ 2.58 | 1.98 % | $ 242 M | USA |
 |
10x Genomics
TXG
|
-230 M | $ 24.55 | 4.11 % | $ 2.88 B | USA |
 |
GoodRx Holdings
GDRX
|
135 M | $ 2.19 | 1.87 % | $ 845 M | USA |
 |
SCWorx Corp.
WORX
|
-958 K | - | - | $ 7.71 M | USA |
 |
Akerna Corp.
KERN
|
-170 M | - | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
253 M | - | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
26.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
NextGen Healthcare
NXGN
|
20.8 M | - | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
-197 M | - | - | $ 3.37 B | USA |
 |
OptimizeRx Corporation
OPRX
|
-24 M | $ 6.09 | 2.7 % | $ 104 M | USA |
 |
Health Catalyst
HCAT
|
-110 M | $ 1.09 | 2.36 % | $ 76.2 M | USA |
 |
HealthEquity
HQY
|
477 M | $ 80.27 | 0.44 % | $ 6.91 B | USA |
 |
Premier
PINC
|
119 M | - | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
-161 M | $ 11.74 | 2.53 % | $ 862 M | USA |
 |
Phreesia
PHR
|
24.8 M | $ 8.68 | 1.4 % | $ 519 M | USA |
 |
R1 RCM
RCM
|
223 M | - | - | $ 3.81 B | USA |
 |
Teladoc Health
TDOC
|
87.8 M | $ 5.3 | 1.53 % | $ 934 M | USA |
 |
Streamline Health Solutions
STRM
|
-3.18 M | - | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
-35.3 M | - | -46.64 % | $ 10.4 M | USA |
 |
American Well Corporation
AMWL
|
-71.3 M | $ 5.57 | 2.2 % | $ 89.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-45.6 M | - | - | $ 255 M | USA |
 |
HealthStream
HSTM
|
62.5 M | $ 20.56 | 0.91 % | $ 625 M | USA |
 |
Omnicell
OMCL
|
82.6 M | $ 35.88 | 2.49 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
19 M | $ 17.04 | 0.35 % | $ 1.46 B | USA |
 |
So-Young International
SY
|
-579 M | $ 2.74 | 1.67 % | $ 218 M |  China |
 |
Veeva Systems
VEEV
|
930 M | $ 159.37 | 0.58 % | $ 26.1 B | USA |
 |
Zhongchao
ZCMD
|
-5.9 M | $ 2.03 | 1.0 % | $ 6.94 M | China |